Meds & supplements › Erdafitinib
Medicine · Kinase Inhibitor
Erdafitinib
BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior…
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
- BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
- Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
What it is used for
BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
Side effects, and when to stop
The following serious adverse reactions are also described elsewhere in the labeling:
- Ocular Disorders.
- Hyperphosphatemia.
Who should not take it
None.
Storing it
Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F).
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Erdafitinib; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/erdafitinib
- APA 7th
sofidex. (2026, August 2). Erdafitinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/erdafitinib
- AMA 11th
Erdafitinib. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/erdafitinib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.